Sei Investments Co. Buys New Stake in Fractyl Health, Inc. (NASDAQ:GUTS)

Sei Investments Co. purchased a new position in shares of Fractyl Health, Inc. (NASDAQ:GUTS) during the fourth quarter, Holdings Channel reports. The fund purchased 27,778 shares of the company’s stock, valued at approximately $57,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Geode Capital Management LLC raised its holdings in shares of Fractyl Health by 166.5% in the 3rd quarter. Geode Capital Management LLC now owns 501,476 shares of the company’s stock valued at $1,269,000 after buying an additional 313,335 shares during the period. BNP Paribas Financial Markets grew its position in Fractyl Health by 54.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 21,072 shares of the company’s stock valued at $53,000 after acquiring an additional 7,397 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Fractyl Health by 56.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 80,664 shares of the company’s stock worth $204,000 after purchasing an additional 29,262 shares during the period. Rhumbline Advisers lifted its position in shares of Fractyl Health by 73.1% during the fourth quarter. Rhumbline Advisers now owns 25,626 shares of the company’s stock worth $53,000 after purchasing an additional 10,826 shares in the last quarter. Finally, Barclays PLC boosted its stake in shares of Fractyl Health by 1,754.7% in the third quarter. Barclays PLC now owns 47,796 shares of the company’s stock valued at $121,000 after purchasing an additional 45,219 shares during the period.

Fractyl Health Stock Up 6.6 %

Fractyl Health stock opened at $1.01 on Friday. The firm has a market capitalization of $49.41 million, a P/E ratio of -0.08 and a beta of 0.30. The company has a current ratio of 5.58, a quick ratio of 5.57 and a debt-to-equity ratio of 0.60. Fractyl Health, Inc. has a twelve month low of $0.87 and a twelve month high of $7.89. The stock’s fifty day simple moving average is $1.34 and its 200-day simple moving average is $1.91.

Fractyl Health (NASDAQ:GUTS) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.08). As a group, equities analysts expect that Fractyl Health, Inc. will post -1.61 earnings per share for the current fiscal year.

Insider Transactions at Fractyl Health

In other news, CEO Harith Rajagopalan sold 90,972 shares of Fractyl Health stock in a transaction on Friday, January 31st. The shares were sold at an average price of $1.82, for a total transaction of $165,569.04. Following the completion of the sale, the chief executive officer now directly owns 491,329 shares of the company’s stock, valued at approximately $894,218.78. The trade was a 15.62 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jay David Caplan sold 22,346 shares of the business’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $1.81, for a total transaction of $40,446.26. Following the transaction, the insider now owns 153,544 shares of the company’s stock, valued at approximately $277,914.64. The trade was a 12.70 % decrease in their position. The disclosure for this sale can be found here.

Wall Street Analyst Weigh In

Separately, Morgan Stanley dropped their price objective on shares of Fractyl Health from $18.00 to $10.00 and set an “overweight” rating for the company in a report on Monday, February 3rd.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.